In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer

Cancer Letters

Volumn 297, Issue 1, 2010, Pages 56-64

  Zhou, Lina ^a   Li, Xingyi ^b   Chen, Xiancheng ^b   Li, Zhiyong ^b   Liu, Xianping ^a   Zhou, Shengtao ^a   Zhong, Qian ^a   Yi, Tao ^a   Wei, Yuquan ^b   Zhao, Xia ^a   Qian, Zhiyong ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Camptothecin; Hepatic cancer; Lymphatic metastasis; Lymphogenesis; TMC

Indexed keywords

CAMPTOTHECIN; CHITOSAN DERIVATIVE; N TRIMETHYL CHITOSAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHITOSAN; DRUG CARRIER; GELATINASE B; MESSENGER RNA; MMP9 PROTEIN, MOUSE; N-TRIMETHYL CHITOSAN CHLORIDE; VASCULOTROPIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; BIOTINYLATION; CACHEXIA; CANCER INHIBITION; DEATH; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; ENCAPSULATION; FEMALE; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ULCER; SURVIVAL TIME; WEIGHT REDUCTION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MEDICINAL CHEMISTRY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SECONDARY; TIME; TOXICITY; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; LIVER NEOPLASMS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; TIME FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

MURINAE; MUS;

EID: 77956227263     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.024     Document Type: Article

References (43)

1. Sleeman J.P. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 2000, 157:55-81.
2. Tobler N.E., Detmar M. Tumor and lymph node lymphangiogenesis: impact on cancer metastasis. J. Leukoc. Biol. 2006, 80:691-696.
3. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
4. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7:186-191.
5. Gallo R.C., Whang-Peng J., Adamson R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 1971, 46:789-795.
6. Herben V.M., ten Bokkel Huinink W.W., Beijnen J.H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 1996, 31:85-102.
7. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260:14873-14878.
8. van Hattum A.H., Pinedo H.M., Schluper H.M., Erkelens C.A., Tohgo A., Boven E. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem. Pharmacol. 2002, 64:1267-1277.
9. Wang L.M., Li Q.Y., Zu Y.G., Fu Y.J., Chen L.Y., Lv H.Y., Yao L.P., Jiang S.G. Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line. Chem. Biol. Interact. 2008, 176:165-172.
10. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., Davis M.E. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006, 12:1606-1614.
11. Lee D.H., Kim S.W., Suh C., Lee J.S., Lee J.H., Lee S.J., Ryoo B.Y., Park K., Kim J.S., Heo D.S., Kim N.K. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann. Oncol. 2008, 19:123-127.
12. Pantazis P., Hinz H.R., Mendoza J.T., Kozielski A.J., Williams L.J., Stehlin J.S., Giovanella B.C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 1992, 52:3980-3987.
13. Potmesil M., Vardeman D., Kozielski A.J., Mendoza J., Stehlin J.S., Giovanella B.C. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res. 1995, 55:5637-5641.
14. Matsuzaki T., Yokokura T., Mutai M., Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 1988, 21:308-312.
15. De Cesare M., Pratesi G., Veneroni S., Bergottoni R., Zunino F. Efficacy of the novel camptothecin Gimatecan against orthotopic and metastatic human tumor xenograft models. Clin. Cancer Res. 2004, 10:7357-7364.
16. Sun F.X., Tohgo A., Bouvet M., Yagi S., Nassirpour R., Moossa A.R., Hoffman R.M. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003, 63:80-85.
17. Haluska P., Rubin E., Verschraegen C.F. Topoisomerase-I inhibitors in gynecologic tumors. Hematol. Oncol. Clin. North Am. 1999, 13:43-61.
18. Zu Y.G., Li Q.Y., Fu Y.J., Wang W. Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. Bioorg. Med. Chem. Lett. 2004, 14:4023-4026.
19. Tardi P., Choice E., Masin D., Redelmeier T., Bally M., Madden T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000, 60:3389-3393.
20. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., Maitani Y. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control Release 2006, 112:329-332.
21. Chen X.C., Lin X.J., Zhao J.L., Shi W., Zhang H., Wang Y.S., Kan B., Du L.C., Wang B.D., Wei Y.Q., Liu Y., Zhao X. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 2008, 16:749-756.
22. Isaka N., Padera T.P., Hagendoorn J., Fukumura D., Jain R.K. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 2004, 64:4400-4404.
23. Tsopelas C., Bevington E., Kollias J., Shibli S., Farshid G., Coventry B., Chatterton B.E. 99mTc-Evans blue dye for mapping contiguous lymph node sequences and discriminating the sentinel lymph node in an ovine model. Ann. Surg. Oncol. 2006, 13:692-700.
24. Dadras S.S., Paul T., Bertoncini J., Brown L.F., Muzikansky A., Jackson D.G., Ellwanger U., Garbe C., Mihm M.C., Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 2003, 162:1951-1960.
25. Poon R.T., Ng I.O., Lau C., Yu W.C., Yang Z.F., Fan S.T., Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol. 2002, 20:1775-1785.
26. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
27. Renyi Vamos F., Tovari J., Fillinger J., Timar J., Paku S., Kenessey I., Ostoros G., Agocs L., Soltesz I., Dome B. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin. Cancer Res. 2005, 11:7344-7353.
28. Hall F.T., Freeman J.L., Asa S.L., Jackson D.G., Beasley N.J. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2003, 129:716-719.
29. Bono P., Wasenius V.M., Heikkila P., Lundin J., Jackson D.G., Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin. Cancer Res. 2004, 10:7144-7149.
30. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopaninen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65:4739-4746.
31. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 2002, 161:947-956.
32. Rubbia Brandt L., Terris B., Giostra E., Dousset B., Morel P., Pepper M.S. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin. Cancer Res. 2004, 10:6919-6928.
33. Gombos Z., Xu X., Chu C.S., Zhang P.J., Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 2005, 11:8364-8371.
34. Yasuoka H., Nakamura Y., Zuo H., Tang W., Takamura Y., Miyauchi A., Nakamura M., Mori I., Kakudo K. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Modern Pathol. 2005, 18:1127-1133.
35. Oliver G., Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 2002, 16:773-783.
36. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001, 61:1786-1790.
37. White J.D., Hewett P.W., Kosuge D., Mcculloch T., Enholm B.C., Carmichael J., Murray J.C. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002, 62:1669-1675.
38. O'Grady A., Dunne C., O'Kelly P., Murphy G.M., Leader M., Kay E. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression. Histopathology 2007, 51:793-804.
39. Wu Z.S., Wu Q., Yang J.H., Wang H.Q., Ding X.D., Yang F., Xu X.C. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 2008, 122:2050-2056.
40. Burke T.G., Mi Z. The structural basis of camptothecin interactions with human serum album: impact on drug stability. J. Med. Chem. 1994, 37:40-46.
41. Wang X.H., Cui F.Z., Feng Q.L., Li J.C., Zhang Y.H. Preparation and characterization of collagen/chitosan matrices as potential biomaterials. J. Bioact. Compat. Pol. 2003, 18:453-467.
42. Majeti N.V., Ravi K. A review of chitin and chitosan applications. React. Funct. Polym. 2000, 46:1-27.
43. Thanou M., Verhoef J.C., Marbach P., Junginger H.E. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo. J. Pharm. Sci. 2000, 89:951-957.